SEC Form 4 · accession 0001209191-17-005760
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Kenneth William Powell
Director
Period of report
Jan 25, 2017
Accepted (ET)
Jan 26, 2017 · 5:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $27.30 | Jan 25, 2017 | A | 16,000 | A | — | Jan 24, 2027 | Common Stock | 16,000 | 16,000 | D |
Explanation of responses
- F1This option will vest and become exercisable in 36 equal monthly installments through January 25, 2020, subject to the reporting person's continuous service as of such vesting dates.